The companies within AddLife continue to develop in line with our priorities. Margins are strengthening in both business areas thanks to continuous development of product portfolios and good cost control. Growth was strong in Labtech, and in Medtech, demand was steadily increasing, but was held back somewhat, mainly due to the timing of capital investments in certain countries. Our acquired companies are contributing further to the positive development of margins and growth. Profit for the period improved by 39 percent in the quarter.
Investors
AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap
AddLife creates value
The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.
AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.

AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.

AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.

Target fulfilment 2024
Earnings growth
Profitability
Dividend
Contact us!
The investor pages contain all published financial information to facilitate investment decisions.
We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.
Contact: [email protected]
IR- and press contacts



Subscribe
Your subscription is now saved and you will receive an email to verify your email address and activate the subscription.